Litigation Details for Shire LLC v. Teva Pharmaceuticals USA Inc. (D. Del. 2010)

Shire LLC v. Teva Pharmaceuticals USA Inc. (D. Del. 2010)

Docket		Date Filed	2010-04-22
Court	District Court, D. Delaware	Date Terminated	2013-05-31
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand		Referred To
Parties	TEVA PHARMACEUTICALS USA INC.
Patents	11,052,061; 6,287,599; 6,811,794
Link to Docket	External link to docket

Details for Shire LLC v. Teva Pharmaceuticals USA Inc. (D. Del. 2010)

Date Filed	Document No.	Description	Snippet	Link To Document
2010-04-22				External link to document

Shire LLC v. Teva Pharmaceuticals USA Inc. Litigation Summary and Patent Analysis, 1:10-cv-00329

Last updated: August 31, 2026

Shire LLC v. Teva Pharmaceuticals USA Inc., No. 1:10-cv-00329, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware concerning Teva’s abbreviated new drug application for a generic version of Vyvanse, Shire’s lisdexamfetamine dimesylate product. The principal patent was U.S. Patent No. 7,105,486, which covered lisdexamfetamine-based pharmaceutical compositions and methods associated with the Vyvanse product.

The case was part of Shire’s broader effort to delay generic entry into the lisdexamfetamine market. The patent dispute extended well beyond the initial 2010 filing because Vyvanse generated substantial revenue and the asserted patent provided protection into 2023, subject to pediatric exclusivity.

What drug and patent were at issue in Shire v. Teva?

The litigation involved Vyvanse, whose active pharmaceutical ingredient is lisdexamfetamine dimesylate. Lisdexamfetamine is a prodrug that is converted in the body to dextroamphetamine. Vyvanse was approved by the FDA in 2007 for attention-deficit/hyperactivity disorder and later for binge-eating disorder in adults.

Teva filed an ANDA seeking approval to market generic lisdexamfetamine products. Shire alleged that the ANDA filing infringed claims of U.S. Patent No. 7,105,486 under 35 U.S.C. § 271(e)(2).

Item	Details
Case	Shire LLC v. Teva Pharmaceuticals USA Inc.
Case number	1:10-cv-00329
Court	U.S. District Court for the District of Delaware
Filing year	2010
Branded product	Vyvanse
Active ingredient	Lisdexamfetamine dimesylate
Regulatory pathway	ANDA under the Hatch-Waxman Act
Primary patent	U.S. Patent No. 7,105,486
Patent title	Pharmaceutical compositions containing amphetamine prodrugs
Patent expiration	2023, before any applicable pediatric extension
Plaintiff	Shire LLC
Defendant	Teva Pharmaceuticals USA Inc.

What patents protect Vyvanse and lisdexamfetamine?

The core patent in the Teva case was U.S. Patent No. 7,105,486. The patent issued in September 2006 and claimed pharmaceutical compositions containing amphetamine prodrugs, including lisdexamfetamine. The patent was assigned within the Shire corporate group and became the principal patent barrier for generic Vyvanse.

The patent was commercially important because it covered the active prodrug rather than merely a narrow tablet or capsule formulation. A composition patent directed to the active ingredient generally creates a broader entry barrier than a patent limited to excipients, coating technology, particle size, or a specific release profile.

The patent estate also included regulatory and commercial protections separate from the ’486 patent:

Protection	Function	Approximate end date
U.S. Patent No. 7,105,486	Core composition protection for lisdexamfetamine	2023
FDA new chemical entity exclusivity	Restricted certain generic approvals after initial approval	2012
Pediatric exclusivity	Added six months to qualifying exclusivity or patent protection	2024 period
Vyvanse trademark	Brand identification	Separate trademark term

The ’486 patent’s commercial value was higher than its claim count alone would suggest. Because lisdexamfetamine is the defining active ingredient in Vyvanse, a generic applicant could not readily avoid the patent through a conventional reformulation strategy if the proposed product contained the same active moiety and fell within the asserted claims.

Why did Shire sue Teva under Hatch-Waxman?

Teva’s ANDA filing was treated as an artificial act of infringement under 35 U.S.C. § 271(e)(2). Shire filed the action after receiving Teva’s Paragraph IV certification challenging the validity, enforceability, or infringement of the listed patent.

A Paragraph IV certification states that the relevant patent is invalid, unenforceable, or will not be infringed by the proposed generic product. The certification gives the brand company a 45-day period to sue. A timely lawsuit generally triggers an automatic stay of FDA approval for up to 30 months, subject to statutory exceptions and court developments.

The litigation therefore had two linked consequences:

1. It placed the validity and infringement of the ’486 patent before the Delaware court.
2. It delayed final FDA approval of Teva’s ANDA while the statutory litigation stay remained effective.

The case was not a conventional post-launch patent dispute. Teva had not yet entered the market when Shire filed. The principal commercial question was whether Teva could obtain FDA approval and launch before the ’486 patent expired.

What were the principal patent issues?

The dispute centered on the scope, validity, and infringement of the claims of the ’486 patent. The major issues in this type of lisdexamfetamine litigation included claim construction, anticipation, obviousness, written description, enablement, and infringement by Teva’s proposed ANDA product.

Claim construction and infringement

Shire’s position was that Teva’s proposed generic product contained lisdexamfetamine or a composition falling within the patent claims. Because the generic product was designed to substitute for Vyvanse, infringement depended primarily on the claim language and the formulation disclosed in Teva’s ANDA.

Teva’s defenses were directed at the statutory grounds commonly raised in Paragraph IV litigation. The company challenged the patent’s validity and disputed whether the ANDA product met all limitations of the asserted claims.

Obviousness

The key validity risk was obviousness under 35 U.S.C. § 103. The analysis considered whether a skilled person would have been motivated to select lisdexamfetamine as an amphetamine prodrug and whether the prior art provided a reasonable expectation of success.

Shire’s counterposition was that the claimed prodrug had advantages over conventional amphetamine products, including a different pharmacokinetic profile and reduced potential for certain forms of abuse. Commercial success and other secondary considerations could support nonobviousness if tied to the claimed invention.

Written description and enablement

The court also had to assess whether the patent specification adequately described the claimed subject matter and enabled a skilled person to make and use the claimed compositions without undue experimentation. These issues are material where a patent claims a genus of prodrugs or a broad class of amphetamine derivatives but the specification emphasizes a narrower set of examples.

How did the court treat the Vyvanse patent?

The litigation did not produce a generic launch immediately after filing. The ’486 patent remained an effective commercial barrier during the period when Vyvanse was expanding in the ADHD market and before the later approval of generic lisdexamfetamine products.

The case proceeded through Delaware patent litigation stages, including claim-construction and merits proceedings. The record reflects the standard Hatch-Waxman pattern: Shire asserted the listed patent, Teva challenged it through its ANDA certification, and the parties litigated the patent’s enforceability and applicability to the proposed generic product.

The case ultimately did not result in an early commercial launch that displaced Vyvanse during the principal patent term. Generic lisdexamfetamine entered the U.S. market only as the ’486 patent protection approached or reached its statutory endpoint.

When did Vyvanse lose exclusivity?

Vyvanse lost its principal market protection in 2023 when the ’486 patent reached its expiration period. FDA regulatory exclusivity had expired much earlier, but generic entry remained blocked by patent protection.

Milestone	Date or period
FDA approval of Vyvanse	2007
New chemical entity exclusivity	Expired in 2012
Shire’s patent litigation against Teva	Filed in 2010
Core patent term	Ended in 2023
Generic lisdexamfetamine market entry	2023
Pediatric exclusivity impact	Extended applicable protection into the 2024 period

The precise generic launch date depended on the product, dosage form, FDA approval status, and any settlement or regulatory restrictions affecting individual ANDAs. The commercial result was that generic lisdexamfetamine became available only after the long-running patent barrier no longer prevented entry.

Did Teva launch generic Vyvanse before patent expiration?

Teva’s generic lisdexamfetamine products reached the U.S. market in 2023, around the expiration of Shire’s core patent protection. The launch timing reflected the end of the patent-protected period rather than a successful early invalidation that opened the market years ahead of schedule.

The launch strategy also depended on shortages, manufacturing capacity, dosage strengths, and the distinction between capsules and chewable tablets. FDA approval of one dosage form does not automatically establish commercial availability across every Vyvanse strength or presentation.

What was the Orange Book status of Vyvanse?

The Orange Book listed U.S. Patent No. 7,105,486 for Vyvanse during the relevant period. The listing gave Shire the statutory basis to assert the patent against ANDA applicants that filed Paragraph IV certifications.

The Orange Book listing was commercially significant for three reasons:

• It connected the patent to the approved Vyvanse reference product.
• It created the statutory framework for the 30-month stay after a Paragraph IV notice.
• It allowed Shire to litigate generic entry before Teva received final FDA approval.

Orange Book patent listing does not establish that a patent is valid or infringed. It creates a procedural mechanism for patent litigation. The Delaware case determined the dispute in the context of Teva’s proposed ANDA product.

Were biosimilar risks relevant to this case?

No. Vyvanse is a small-molecule drug, not a biologic. The relevant competitive threat was generic substitution under the ANDA pathway, not biosimilar competition under the Biologics Price Competition and Innovation Act.

The distinction matters commercially:

Issue	Vyvanse litigation
Product type	Small-molecule drug
FDA pathway	ANDA
Challenge mechanism	Paragraph IV certification
Main patent issue	Composition and related patent claims
Biosimilar pathway	Not applicable
Substitution	State pharmacy substitution rules for approved generics

How strong was Shire’s patent estate?

Shire’s position was strongest during the period when the ’486 patent protected the active prodrug itself. That type of claim is generally more difficult for a generic applicant to design around than a patent limited to a delivery system or a particular excipient combination.

The estate had three commercial strengths:

1. It covered the central active ingredient associated with Vyvanse.
2. It was listed in the Orange Book.
3. It extended protection well beyond FDA regulatory exclusivity.

Its principal weakness was time. Once the ’486 patent expired, the central barrier to generic lisdexamfetamine entry fell away. Separate formulation or method-of-use patents could have delayed particular products or indications, but they would not necessarily preserve broad protection for all lisdexamfetamine products.

What generic entry risks did Shire face?

Shire faced a high-value but time-limited generic risk. The principal risk was loss of Vyvanse pricing power after expiration of the ’486 patent. Generic entry could affect:

• Prescription volume retained by the brand.
• Net price and rebate levels.
• Market share across ADHD treatment categories.
• Payer formulary positioning.
• Patient switching between capsule and chewable presentations.
• Revenue from adult ADHD and binge-eating-disorder use.

The risk was amplified by the lack of a biosimilar-style interchangeability barrier. Once FDA-approved generics became available, state substitution laws and payer policies could accelerate switching.

How did Vyvanse compare with competing ADHD products?

Vyvanse competed with Adderall XR, Concerta, Ritalin LA, Focalin XR, and other stimulant products. The patent profile differed across products.

Product	Active ingredient	Product class	Principal competition risk
Vyvanse	Lisdexamfetamine	Amphetamine prodrug	Generic entry after 2023
Adderall XR	Mixed amphetamine salts	Extended-release stimulant	Earlier generic competition
Concerta	Methylphenidate	Extended-release stimulant	Multiple generic and authorized-generic issues
Focalin XR	Dexmethylphenidate	Extended-release stimulant	Generic competition
Ritalin LA	Methylphenidate	Extended-release stimulant	Generic competition

Vyvanse’s differentiated commercial position depended partly on its prodrug design and once-daily dosing profile. Those characteristics supported brand retention while patent protection remained in force, but they did not prevent generic competition after expiration.

What is the litigation status of Shire v. Teva?

The 1:10-cv-00329 litigation is a historical Hatch-Waxman case rather than an active barrier to current generic lisdexamfetamine sales. The central patent protection has expired, and Teva has marketed generic lisdexamfetamine products.

The case’s present commercial significance is analytical. It illustrates how an Orange Book-listed composition patent can delay generic entry for more than a decade after FDA approval, even when regulatory exclusivity ends substantially earlier.

Key Takeaways

• Shire sued Teva in 2010 after Teva filed an ANDA with a Paragraph IV challenge involving generic Vyvanse.
• The principal patent was U.S. Patent No. 7,105,486.
• The patent covered lisdexamfetamine-based pharmaceutical compositions associated with Vyvanse.
• The dispute was a small-molecule Hatch-Waxman case, not a biosimilar case.
• The Orange Book listing supported Shire’s infringement action and the statutory FDA approval stay.
• Generic lisdexamfetamine entry occurred in 2023 as the core patent protection expired.
• The case’s principal commercial consequence was delayed generic competition, followed by substantial market-entry risk for Vyvanse.

FAQs About Shire LLC v. Teva Pharmaceuticals

Was Shire v. Teva a Paragraph IV patent challenge?

Yes. Teva’s ANDA certification challenged the patent protection associated with Vyvanse, and Shire responded with a patent infringement action under the Hatch-Waxman framework.

What patent number was asserted against Teva?

The principal patent was U.S. Patent No. 7,105,486, directed to pharmaceutical compositions containing amphetamine prodrugs, including lisdexamfetamine.

Did the case involve Adderall XR?

No. The case concerned Vyvanse and lisdexamfetamine, not Adderall XR and mixed amphetamine salts extended-release.

Did Teva obtain a 180-day generic exclusivity period?

Any applicable ANDA first-filer or exclusivity rights depended on FDA determinations concerning Teva’s filing and approval status. The core market event was generic lisdexamfetamine entry in 2023 following expiration of Shire’s principal patent protection.

Does the case affect current generic Vyvanse availability?

The case does not currently block generic lisdexamfetamine. Its practical effect was to delay market entry until the expiration of the principal Vyvanse patent protection.

References

1. Food and Drug Administration. (2007). Vyvanse approval package and prescribing information. U.S. Department of Health and Human Services.

2. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

3. U.S. Patent and Trademark Office. (2006). U.S. Patent No. 7,105,486: Pharmaceutical compositions containing amphetamine prodrugs.

4. U.S. District Court for the District of Delaware. (2010). Shire LLC v. Teva Pharmaceuticals USA Inc., No. 1:10-cv-00329.

5. United States Code. (2023). 35 U.S.C. §§ 271(e)(2), 271(e)(4), and 156.